Concepts (195)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myositis Ossificans | 4 | 2023 | 76 | 2.790 |
Why?
|
| Niemann-Pick Disease, Type C | 3 | 2024 | 57 | 2.580 |
Why?
|
| Ossification, Heterotopic | 3 | 2023 | 239 | 1.780 |
Why?
|
| Fibrous Dysplasia, Polyostotic | 2 | 2024 | 39 | 1.710 |
Why?
|
| Pain | 15 | 2024 | 5076 | 1.640 |
Why?
|
| Fibrous Dysplasia of Bone | 1 | 2024 | 52 | 0.870 |
Why?
|
| Neuralgia | 3 | 2024 | 620 | 0.790 |
Why?
|
| Somatosensory Disorders | 1 | 2022 | 49 | 0.770 |
Why?
|
| Choroid Plexus | 1 | 2024 | 250 | 0.760 |
Why?
|
| Somatoform Disorders | 1 | 2024 | 425 | 0.740 |
Why?
|
| Osteochondrodysplasias | 1 | 2022 | 183 | 0.740 |
Why?
|
| Lysosomal Storage Diseases | 1 | 2021 | 80 | 0.730 |
Why?
|
| Nerve Net | 5 | 2021 | 2310 | 0.710 |
Why?
|
| Endocrine System Diseases | 1 | 2023 | 243 | 0.700 |
Why?
|
| Brain | 15 | 2021 | 27178 | 0.690 |
Why?
|
| Opioid-Related Disorders | 3 | 2022 | 2176 | 0.670 |
Why?
|
| Neuromuscular Diseases | 1 | 2021 | 260 | 0.590 |
Why?
|
| Magnetic Resonance Imaging | 29 | 2024 | 36542 | 0.590 |
Why?
|
| Pain Measurement | 8 | 2022 | 3559 | 0.580 |
Why?
|
| Reward | 2 | 2021 | 980 | 0.560 |
Why?
|
| Central Nervous System Diseases | 1 | 2021 | 519 | 0.560 |
Why?
|
| Buprenorphine | 4 | 2013 | 665 | 0.540 |
Why?
|
| Diffusion Tensor Imaging | 3 | 2024 | 2415 | 0.540 |
Why?
|
| Activins | 1 | 2017 | 210 | 0.510 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2022 | 4627 | 0.490 |
Why?
|
| Analgesia | 2 | 2017 | 461 | 0.470 |
Why?
|
| Hot Temperature | 4 | 2015 | 1433 | 0.430 |
Why?
|
| Auditory Cortex | 2 | 2008 | 364 | 0.430 |
Why?
|
| Sciatic Neuropathy | 1 | 2013 | 75 | 0.420 |
Why?
|
| Executive Function | 1 | 2021 | 1391 | 0.410 |
Why?
|
| Child Abuse | 1 | 2022 | 1090 | 0.410 |
Why?
|
| Mental Disorders | 2 | 2023 | 6872 | 0.400 |
Why?
|
| Neuropharmacology | 1 | 2011 | 19 | 0.380 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2024 | 2152 | 0.370 |
Why?
|
| Psychotic Disorders | 1 | 2024 | 3272 | 0.320 |
Why?
|
| Brain Mapping | 10 | 2018 | 6598 | 0.310 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2009 | 240 | 0.300 |
Why?
|
| Neural Pathways | 4 | 2021 | 3087 | 0.290 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 3 | 2008 | 2805 | 0.290 |
Why?
|
| Wakefulness | 2 | 2011 | 1281 | 0.280 |
Why?
|
| Afferent Pathways | 1 | 2008 | 303 | 0.280 |
Why?
|
| Trigeminal Nerve | 1 | 2008 | 253 | 0.270 |
Why?
|
| Analgesics, Opioid | 3 | 2013 | 3834 | 0.270 |
Why?
|
| Analgesics | 2 | 2020 | 1057 | 0.260 |
Why?
|
| Spectrum Analysis | 1 | 2007 | 443 | 0.250 |
Why?
|
| Aspartic Acid | 1 | 2007 | 575 | 0.240 |
Why?
|
| Action Potentials | 1 | 2012 | 1837 | 0.240 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 1885 | 0.230 |
Why?
|
| Osteoarthritis | 1 | 2012 | 1050 | 0.230 |
Why?
|
| Humans | 46 | 2024 | 765823 | 0.230 |
Why?
|
| Brain Stem | 1 | 2008 | 854 | 0.210 |
Why?
|
| Adolescent | 9 | 2024 | 88794 | 0.210 |
Why?
|
| Corpus Callosum | 1 | 2007 | 751 | 0.200 |
Why?
|
| Sulfonamides | 1 | 2012 | 1981 | 0.200 |
Why?
|
| Inflammation | 1 | 2022 | 10845 | 0.190 |
Why?
|
| Pyrazoles | 1 | 2012 | 2031 | 0.190 |
Why?
|
| Myography | 1 | 2022 | 111 | 0.190 |
Why?
|
| Adult | 18 | 2024 | 223055 | 0.180 |
Why?
|
| Catastrophization | 1 | 2024 | 352 | 0.180 |
Why?
|
| Spinal Cord | 1 | 2008 | 1786 | 0.170 |
Why?
|
| Activin Receptors, Type I | 1 | 2021 | 133 | 0.170 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2015 | 8927 | 0.170 |
Why?
|
| Post-Traumatic Headache | 1 | 2021 | 70 | 0.170 |
Why?
|
| Motor Skills Disorders | 1 | 2020 | 89 | 0.160 |
Why?
|
| Models, Neurological | 2 | 2022 | 1748 | 0.160 |
Why?
|
| Axons | 1 | 2007 | 1678 | 0.160 |
Why?
|
| Putamen | 1 | 2020 | 289 | 0.160 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2008 | 3359 | 0.160 |
Why?
|
| Psychopathology | 1 | 2022 | 434 | 0.160 |
Why?
|
| Male | 25 | 2024 | 363740 | 0.150 |
Why?
|
| Complex Regional Pain Syndromes | 1 | 2020 | 122 | 0.150 |
Why?
|
| Child | 6 | 2024 | 80509 | 0.150 |
Why?
|
| Electric Impedance | 1 | 2022 | 793 | 0.150 |
Why?
|
| Young Adult | 7 | 2024 | 59849 | 0.150 |
Why?
|
| Diphosphonates | 1 | 2023 | 625 | 0.150 |
Why?
|
| Muscles | 1 | 2022 | 1578 | 0.150 |
Why?
|
| Rare Diseases | 1 | 2023 | 629 | 0.150 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2007 | 3677 | 0.140 |
Why?
|
| Disease Models, Animal | 2 | 2017 | 18289 | 0.140 |
Why?
|
| Cerebrum | 1 | 2018 | 132 | 0.140 |
Why?
|
| Comorbidity | 2 | 2022 | 10570 | 0.140 |
Why?
|
| Avoidance Learning | 1 | 2018 | 248 | 0.140 |
Why?
|
| Age of Onset | 1 | 2024 | 3341 | 0.130 |
Why?
|
| Central Nervous System | 1 | 2024 | 1342 | 0.130 |
Why?
|
| Prefrontal Cortex | 2 | 2021 | 2223 | 0.130 |
Why?
|
| Cerebellum | 1 | 2023 | 1519 | 0.130 |
Why?
|
| Lysosomes | 1 | 2021 | 932 | 0.130 |
Why?
|
| Drug Design | 2 | 2011 | 1040 | 0.130 |
Why?
|
| X-Ray Microtomography | 1 | 2017 | 454 | 0.120 |
Why?
|
| Blood-Brain Barrier | 1 | 2021 | 1037 | 0.120 |
Why?
|
| Rats | 5 | 2013 | 23707 | 0.110 |
Why?
|
| Phenotype | 2 | 2023 | 16706 | 0.110 |
Why?
|
| Autophagy | 1 | 2021 | 1352 | 0.110 |
Why?
|
| Oxygen | 4 | 2015 | 4242 | 0.110 |
Why?
|
| Nalbuphine | 1 | 2013 | 20 | 0.110 |
Why?
|
| Fluorescence Polarization | 1 | 2013 | 140 | 0.110 |
Why?
|
| Acoustic Stimulation | 2 | 2008 | 1254 | 0.100 |
Why?
|
| Knee Joint | 1 | 2021 | 1657 | 0.100 |
Why?
|
| Bone and Bones | 1 | 2023 | 2555 | 0.100 |
Why?
|
| Administration, Sublingual | 1 | 2011 | 60 | 0.100 |
Why?
|
| Drug Discovery | 2 | 2017 | 1063 | 0.100 |
Why?
|
| Gyrus Cinguli | 2 | 2023 | 1116 | 0.100 |
Why?
|
| Female | 12 | 2024 | 396050 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2013 | 10723 | 0.090 |
Why?
|
| Cross-Over Studies | 3 | 2013 | 2108 | 0.090 |
Why?
|
| Pulvinar | 1 | 2011 | 24 | 0.090 |
Why?
|
| Rats, Long-Evans | 1 | 2011 | 380 | 0.090 |
Why?
|
| Caregivers | 1 | 2023 | 2304 | 0.090 |
Why?
|
| Touch | 2 | 2010 | 308 | 0.090 |
Why?
|
| Rats, Inbred Lew | 1 | 2012 | 1166 | 0.090 |
Why?
|
| Respiratory Rate | 1 | 2011 | 179 | 0.090 |
Why?
|
| Guidelines as Topic | 3 | 2011 | 1393 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2022 | 8725 | 0.080 |
Why?
|
| Clinical Trials as Topic | 3 | 2011 | 8039 | 0.080 |
Why?
|
| Confidence Intervals | 1 | 2015 | 2914 | 0.080 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 1375 | 0.080 |
Why?
|
| Brain Concussion | 1 | 2021 | 1432 | 0.080 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2010 | 187 | 0.080 |
Why?
|
| Trigeminal Neuralgia | 1 | 2010 | 108 | 0.080 |
Why?
|
| Trigeminal Nucleus, Spinal | 1 | 2008 | 23 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2024 | 54798 | 0.080 |
Why?
|
| Statistics as Topic | 1 | 2015 | 2350 | 0.080 |
Why?
|
| Animals | 9 | 2017 | 168730 | 0.070 |
Why?
|
| Triazines | 1 | 2010 | 306 | 0.070 |
Why?
|
| Neurosciences | 1 | 2013 | 385 | 0.070 |
Why?
|
| Physical Stimulation | 1 | 2009 | 513 | 0.070 |
Why?
|
| Proteomics | 1 | 2022 | 3909 | 0.070 |
Why?
|
| Organ Specificity | 1 | 2013 | 1964 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2013 | 8105 | 0.070 |
Why?
|
| Bipolar Disorder | 1 | 2024 | 5127 | 0.070 |
Why?
|
| Optic Nerve | 1 | 2011 | 568 | 0.070 |
Why?
|
| Basal Ganglia | 1 | 2010 | 549 | 0.070 |
Why?
|
| Pharmaceutical Preparations | 2 | 2017 | 1084 | 0.070 |
Why?
|
| Drug Evaluation | 1 | 2008 | 641 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2015 | 6204 | 0.070 |
Why?
|
| Visual Pathways | 1 | 2011 | 556 | 0.070 |
Why?
|
| Parietal Lobe | 1 | 2011 | 859 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 15881 | 0.070 |
Why?
|
| Hypothalamus | 1 | 2011 | 995 | 0.070 |
Why?
|
| Schizophrenia | 1 | 2024 | 6970 | 0.060 |
Why?
|
| Diffusion | 1 | 2007 | 808 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 26276 | 0.060 |
Why?
|
| Ketamine | 1 | 2010 | 525 | 0.060 |
Why?
|
| Middle Aged | 6 | 2024 | 223016 | 0.060 |
Why?
|
| Double-Blind Method | 3 | 2013 | 12421 | 0.050 |
Why?
|
| Nerve Fibers | 1 | 2006 | 703 | 0.050 |
Why?
|
| Amygdala | 1 | 2010 | 1376 | 0.050 |
Why?
|
| Quality of Life | 1 | 2024 | 13466 | 0.050 |
Why?
|
| Neuroprotective Agents | 1 | 2008 | 958 | 0.050 |
Why?
|
| Probability | 1 | 2006 | 2475 | 0.050 |
Why?
|
| Functional Laterality | 1 | 2008 | 2243 | 0.050 |
Why?
|
| Anticonvulsants | 1 | 2010 | 1919 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2023 | 20680 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 20131 | 0.040 |
Why?
|
| Brain Diseases | 1 | 2008 | 1551 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2022 | 42478 | 0.040 |
Why?
|
| Quality Control | 2 | 2011 | 835 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 2013 | 2226 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 6545 | 0.030 |
Why?
|
| Hand Strength | 1 | 2020 | 462 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2007 | 2859 | 0.030 |
Why?
|
| Anxiety | 1 | 2011 | 4670 | 0.030 |
Why?
|
| Mutation | 1 | 2021 | 30188 | 0.030 |
Why?
|
| Cerebral Cortex | 1 | 2011 | 5764 | 0.030 |
Why?
|
| Drug Industry | 2 | 2011 | 791 | 0.030 |
Why?
|
| Software | 1 | 2006 | 4458 | 0.030 |
Why?
|
| Psychophysics | 1 | 2013 | 294 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2021 | 81505 | 0.020 |
Why?
|
| Receptors, Neurokinin-1 | 1 | 2012 | 133 | 0.020 |
Why?
|
| Receptors, Opioid, mu | 1 | 2013 | 165 | 0.020 |
Why?
|
| Mice | 1 | 2017 | 81788 | 0.020 |
Why?
|
| Photophobia | 1 | 2011 | 87 | 0.020 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2011 | 161 | 0.020 |
Why?
|
| Naloxone | 1 | 2013 | 373 | 0.020 |
Why?
|
| Normal Distribution | 1 | 2010 | 267 | 0.020 |
Why?
|
| Blood Gas Analysis | 1 | 2010 | 382 | 0.020 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2010 | 139 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2011 | 41643 | 0.020 |
Why?
|
| Amines | 1 | 2010 | 281 | 0.020 |
Why?
|
| Species Specificity | 1 | 2013 | 2406 | 0.020 |
Why?
|
| Cold Temperature | 1 | 2010 | 794 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 1659 | 0.020 |
Why?
|
| Amino Acids | 1 | 2010 | 1709 | 0.010 |
Why?
|
| Drug Monitoring | 1 | 2010 | 960 | 0.010 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2010 | 1139 | 0.010 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2010 | 1456 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2010 | 6014 | 0.010 |
Why?
|
| Decision Making | 1 | 2012 | 3955 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2010 | 6252 | 0.010 |
Why?
|
| Models, Biological | 1 | 2010 | 9441 | 0.010 |
Why?
|
| Algorithms | 1 | 2010 | 14062 | 0.010 |
Why?
|
| Time Factors | 1 | 2010 | 40109 | 0.000 |
Why?
|
| Aged | 1 | 2020 | 171178 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2010 | 65223 | 0.000 |
Why?
|
| United States | 1 | 2008 | 72896 | 0.000 |
Why?
|
Concepts
(195)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(56)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_